Rothschild & CO Asset Management Us Inc. Halozyme Therapeutics, Inc. Transaction History
Rothschild & CO Asset Management Us Inc.
- $6.56 Billion
- Q4 2022
A detailed history of Rothschild & CO Asset Management Us Inc. transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Rothschild & CO Asset Management Us Inc. holds 176,487 shares of HALO stock, worth $9.18 Million. This represents 0.15% of its overall portfolio holdings.
Number of Shares
176,487
Previous 182,683
3.39%
Holding current value
$9.18 Million
Previous $7.22 Million
39.03%
% of portfolio
0.15%
Previous 0.12%
Shares
5 transactions
Others Institutions Holding HALO
# of Institutions
442Shares Held
122MCall Options Held
216KPut Options Held
140K-
Black Rock Inc. New York, NY18.2MShares$949 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA13MShares$679 Million0.01% of portfolio
-
State Street Corp Boston, MA6.49MShares$337 Million0.01% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.12MShares$214 Million3.73% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.79MShares$197 Million0.24% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $7.24B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...